105 related articles for article (PubMed ID: 2231757)
1. Prediction of postoperative clinical course by autologous tumor-killing activity in lung cancer patients.
Uchida A; Kariya Y; Okamoto N; Sugie K; Fujimoto T; Yagita M
J Natl Cancer Inst; 1990 Nov; 82(21):1697-701. PubMed ID: 2231757
[TBL] [Abstract][Full Text] [Related]
2. [Autologous tumor killing (ATK) and tumor metastasis in human cancer patients].
Uchida A; Kariya Y
Hum Cell; 1993 Mar; 6(1):15-20. PubMed ID: 8343445
[TBL] [Abstract][Full Text] [Related]
3. Lysis of fresh human tumor cells by autologous large granular lymphocytes and T-lymphocytes: two distinct killing activities induced by coculture with autologous tumor.
Uchida A; Moore M
J Natl Cancer Inst; 1984 Dec; 73(6):1285-92. PubMed ID: 6239944
[TBL] [Abstract][Full Text] [Related]
4. Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung.
Fujisawa T; Yamaguchi Y
Cancer; 1997 Feb; 79(3):474-81. PubMed ID: 9028357
[TBL] [Abstract][Full Text] [Related]
5. Lysis of fresh human tumour cells by autologous tumour-associated lymphocytes: two distinct types of autologous tumour killer cells induced by co-culture with autologous tumour.
Uchida A; Moore M
Cancer Immunol Immunother; 1985; 20(1):29-37. PubMed ID: 3877561
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell activity and autologous tumor killing activity in cancer patients: overlapping involvement of effector cells as determined in two-target conjugate cytotoxicity assay.
Uchida A; Yanagawa E
J Natl Cancer Inst; 1984 Nov; 73(5):1093-100. PubMed ID: 6593485
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
Mizutani Y; Okada Y; Terachi T; Yoshida O
J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
[TBL] [Abstract][Full Text] [Related]
8. Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer.
Mizutani Y; Okada Y; Yoshida O; Bonavida B
Cancer Biother Radiopharm; 1996 Dec; 11(6):385-91. PubMed ID: 10851499
[TBL] [Abstract][Full Text] [Related]
9. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432.
Uchida A; Micksche M
J Natl Cancer Inst; 1983 Oct; 71(4):673-80. PubMed ID: 6413742
[TBL] [Abstract][Full Text] [Related]
10. Suppression of T-cell response in autologous mixed lymphocyte-tumor culture by large granular lymphocytes.
Uchida A; Klein E
J Natl Cancer Inst; 1986 Mar; 76(3):389-98. PubMed ID: 2419621
[TBL] [Abstract][Full Text] [Related]
11. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-activated peripheral blood lymphocytes and tumor infiltrating lymphocytes.
Mizutani Y; Yoshida O; Miki T
J Urol; 1999 Dec; 162(6):2170-5. PubMed ID: 10569614
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of autologous tumor killing (ATK) activity and its induction therapy in human cancer.
Uchida A
Biotherapy; 1994; 8(2):113-22. PubMed ID: 8924352
[TBL] [Abstract][Full Text] [Related]
13. Intrapleural administration of OK432 in cancer patients: augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes.
Uchida A; Micksche M; Hoshino T
Cancer Immunol Immunother; 1984; 18(1):5-12. PubMed ID: 6333269
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer.
Pisani RJ; Krco CJ; Wold LE; McKean DJ
Am J Clin Pathol; 1989 Oct; 92(4):435-46. PubMed ID: 2552792
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
16. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells.
Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N
Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523
[TBL] [Abstract][Full Text] [Related]
17. Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy.
Yamasaki S; Kan N; Harada T; Ichinose Y; Moriguchi Y; Li L; Sugie T; Kodama H; Satoh K; Ohgaki K
Breast Cancer Res Treat; 1993; 26(1):55-65. PubMed ID: 8400324
[TBL] [Abstract][Full Text] [Related]
18. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
[TBL] [Abstract][Full Text] [Related]
19. Selective lysis of the autologous tumor by delta TCS1+ gamma/delta+ tumor-infiltrating lymphocytes from human lung carcinomas.
Zocchi MR; Ferrarini M; Rugarli C
Eur J Immunol; 1990 Dec; 20(12):2685-9. PubMed ID: 1702723
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
